Mostafa Faisal Mohammed Saleh: From HLA Biology to Curative Therapy
Mostafa Faisal Mohammed Saleh, Associate Professor of Clinical Hematology and HSCT at Assiut University, shared a post on LinkedIn:
”Twenty Years in Hematology: From the Palpable Spleen to Cellular Therapy
A personal journey, 2006–2026
Part 2
At the same time, I began to get deeply involved in stem cell transplantation.
The possibility of curing diseases that had reached the limits of conventional treatment was extraordinary.
As physicians, we sometimes miss the immediate satisfaction our surgical colleagues experience after removing a tumor or repairing an organ.
Transplantation gave me a similar feeling: a patient with an otherwise fatal hematologic disease could undergo an extraordinarily complex treatment and potentially emerge cured.
A major turning point came in December 2013, when I joined the Cleveland Clinic as a research fellow in Histocompatibility and Immunogenetics. I entered what I thought of as ‘HLA land.’
I learned transplantation from another perspective—donor matching, HLA, KIR biology, immunogenetics, and their relationship to transplant outcomes.
Equally influential were the BMT rounds with physicians including Navneet Majhail and Ronald Sobecks, where laboratory immunology became directly connected to patients at the bedside.
My research during this period, including work on donor KIR genotype and transplantation outcomes, became closely linked to my PhD research in transplantation and pharmacogenetics.
After completing my PhD in Clinical Hematology and Stem Cell Transplantation in 2016, I continued patient care, teaching, and transplantation in Egypt.
Participating in the development of the first bone marrow transplantation experience in Upper Egypt in 2016 was particularly meaningful.
Bringing this potentially curative treatment closer to patients who previously had to travel to Cairo reinforced my belief that medical progress matters most when it becomes accessible to the patients who need it.”
Stay updated with Hemostasis Today.
-
Oct 28, 2026, 14:56Elizabeth Shirley: COVID-19 Vaccines, Spike Protein and Nitric Oxide Bioavailability
-
Oct 28, 2026, 14:39David Ledger: Anticoagulation Advances as Factor XIa Inhibition Reaches a New Milestone
-
Oct 28, 2026, 14:37Advancing Liver Health in Haemophilia Care – EAHAD
-
Oct 28, 2026, 14:34The Changing Landscape of Anticoagulant Therapy – ISTH
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters